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Despite expressing antigens recognizable by a host's immune system, tumors are very poor in initiating effective immune responses. One reason for this poor immunogenicity may be that the presentation of antigen alone is insufficient to activate T cells. In addition to T cell receptor engagement of an antigenic peptide bound to major histocompatibility complex (MHC) molecules, additional costimulatory signals are necessary for T cell activation (1) . The most important of these costimulatory signals appears to be provided by the interaction of CD28 on T cells with its primary ligands B7-1 (CD80) and B7-2 (CD86) on the surface of specialized antigen-presenting cells (APCs) (2-4). Expression of B7 costimulatory molecules is limited to specialized APCs. Therefore, even though most tissue-derived tumors may present antigen in the context of MHC molecules, they may fail to elicit effective immunity because of a lack of costimulatory ability. Several studies support this notion. In a variety of model systems, transfected tumor cells expressing costimulatory B7 molecules induced potent responses against both modified and unmodified tuLmor cells (5) (6) (7) (8) 
tumor cells transfected with B7 are able to behave as APCs, presumably allowing direct activation of tumor-specific T cells.
Recent evidence suggests that costimulation is more complex than originally thought and involves competing stimulatory and inhibitory signaling events (3, 9-12). CTLA-4, a homolog of CD28, binds both B7-1 and B7-2 with affinities much greater than does CD28 (13-16). In vitro, antibody cross-linking of CTLA-4 has been shown to inhibit T cell proliferation and interleukin-2 production induced by antibody to CD3 (anti-CD3), whereas blockade of CTLA-4 with soluble intact or Fab fragments of antibody enhances proliferative responses (17, 18) 
. Similarly, soluble intact or Fab fragments of anti-CTLA-4 greatly augment T. cell responses to nominal peptide antigen or the superantigen Staphylococcus enterotoxin B in vivo (1 9, 20). It has also been suggested that CTLA-4 engagement can induce apoptosis in activated T cells (21). Finally, mice deficient in CTLA-4 exhibit severe T cell proliferative disorders (22). These results demonstrate that CTLA-4 is a negative regulator of T cell responses and raise the possibility that blockade of inhibitory signals delivered by

CTLA-4-B7 interactions might augment T cell responses to tumor cells and enhance antitumor immunity.
We first sought to determine whether tumor cells and left untreated, or treated with anti-CD28, developed progressively growing tumors and required euthanasia by 35 days after inoculation ( Fig. 2A) . In contrast, all mice treated with anti-CTLA-4 completely rejected their tumors after a short period of limited growth. Similarly, control mice injected with 2 x 106 tumor cells developed rapidly growing tumors and required euthanasia by day 35 (Fig. 2B) . Anti-CTLA-4 treatment had a dramatic effect on tumor growth, but one mouse did develop a tumor quickly (accounting for a majority of the growth indicated in Fig. 2B ) and another developed a tumor much later (Fig. 2C) .
Anti-CTLA-4 appeared to be less effective at a tumor dose of 1 x 106 cells, where treatment resulted in significantly reduced tumor growth rates, but four of five mice developed progressively growing tumors (25). Thus, although curative responses were not obtained in all cases, it is clear that CTLA-4 blockade significantly enhanced rejection of B7-negative tumor cells.
We next sought to determine whether tumor rejection as a consequence of CTLA-4 blockade was associated with enhanced immunity to a secondary challenge. Mice that had rejected V51BLimlO tumor cells as a result of treatment with anti-CTLA-4 were challenged with 4 X 106 wildtype 51BLimlO cells 70 days after their ini-tial tumor injections. These mice showed significant protection against a secondary challenge as compared with naive controls (Fig. 2D ). All control animals had progressively growing tumors by 14 days after injection, developed massive tumor burdens, and required euthanasia by day 35. Only one of the previously immunized mice had a detectable tumor by day 14, and growth of this tumor was very slow. Ultimately, two more tumors developed in the immunized mice 42 days after challenge. Two mice remained tumor-free throughout the course of the experiment. These results demonstrate that tumor rejection mediated by CTLA-4 blockade results in immunologic memory.
To determine whether anti-CTLA-4 treatment could have an effect on the growth of established tumors, we injected groups of mice with 2 x 106' wild-type 51BLimlO tumor cells and treated them with anti-CTLA-4 beginning on day 0 as before, or beginning 7 days later at which time most mice had palpable tumors. Mice treated with anti-CTLA-4 at either time period had significantly reduced tumor growth compared with untreated controls (Fig. 3) . In fact, delaying treatment appeared to be more effective, with two of five mice remaining tumor-free beyond 30 days after inoculation.
The were not limited to variants of the murine colon carcinoma 51BLimlO. Similar results were obtained with a rapidly growing fibrosarcoma of A/JCr mice, SaiN (26) (Fig. 4) . All control mice injected subcutaneously with 1 X 106 SaiN cells developed measur- 
First, removal of inhibitory signals may lower the overall threshold of T cell activation and allow normally unreactive T cells to become activated. Alternatively, CTLA-4 blockade might sustain proliferation of activated T cells by removing inhibitory signals that would normally terminate the response, thus allowing for greater expansion of tumor-specific T cells.
Regardless of the mechanism, it is clear that CTLA-4 blockade enhances antitumor responses. Most importantly, we have observed these effects against unmanipulated, wild-type tumors. Current methods of enhancing antitumor immunity generally require the engineering of tumor cells (8). Some of these methods, such as the induction of B7 expression, rely on enhancing the costimulatory activity of the tumor cells themselves. Others, such as engineering tumor cells to express MHC class II molecules (26, 28, 29) or to produce granulocyte-macrophage colony-stimulating factor (27, 30, 31) or pulsing dendritic cells with tumor antigen ex vivo (32, 33), seek to enhance antigen presentation, antigen transfer, or both. Thus, CTLA-4 blockade, by removing potentially competing inhibitory signals, may be a particularly useful adjunct to other therapeutic approaches involving the costimulatory pathway.
Two genes, period (per) and timeless (tim), are required for production of circadian rhythms in Drosophila. The proteins encoded by these genes (PER and TIM) physically interact, and the timing of their association and nuclear localization is believed to promote cycles of per and tim transcription through an autoregulatory feedback loop. Here it is shown that TIM protein may also couple this molecular pacemaker to the environment, because TIM is rapidly degraded after exposure to light. TIM accumulated rhythmically in nuclei of eyes and in pacemaker cells of the brain. The phase of these rhythms was differentially advanced or delayed by light pulses delivered at different times of day, corresponding with phase shifts induced in the behavioral rhythms. In the fruit fly Drosophila melarnogaster, two genes, period (3) and timeless (4), are
Circadian rhythms, found in most eukaryotes and some prokaryotes (1), are -24-hour rhythms governed by an internal clock that functions autonomously but can
